Skip to main content

Lonsurf FDA Approval History

FDA Approved: Yes (First approved September 22, 2015)
Brand name: Lonsurf
Generic name: tipiracil hydrochloride and trifluridine
Dosage form: Capsules
Company: Taiho Oncology, Inc.
Treatment for: Colorectal Cancer, Gastric Cancer

Lonsurf (tipiracil and trifluridine) is a thymidine phosphorylase inhibitor and nucleoside metabolic inhibitor combination indicated for the treatment of patients with previously treated metastatic colorectal cancer, and previously treated metastatic gastric or gastroesophageal junction adenocarcinoma.

Development Timeline for Lonsurf

Feb 25, 2019Approval  FDA Approves Lonsurf (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Sep 22, 2015Approval  FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer
Feb 23, 2015Taiho Oncology, Inc. Announces TAS-102 NDA for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.